A New Calculus for Childbirth: The Predictive Power of a Single Blood Test

SALT LAKE CITY, UT – August 25, 2026 – For decades, the American healthcare system has treated preterm birth—a complication affecting one in ten pregnancies—as an unavoidable crisis. The United States consistently earns a near-failing “D+” grade from the March of Dimes for its high rates, and the annual cost of managing the fallout tops an estimated $25 billion. The standard of care has been largely reactive, with physicians only able to identify about 20% of at-risk women using traditional methods like prior birth history, leaving the vast majority of families blindsided.

Now, a strategic shift from reaction to prediction is gaining momentum, powered by a single blood test. Sera Prognostics, a Salt Lake City-based diagnostics company, is at the forefront of this change with its PreTRM® Test. This proteomic analysis, administered between weeks 18 and 21 of pregnancy, provides an individualized risk score for spontaneous preterm birth. Backed by robust clinical trial data, the test enables a crucial pivot: armed with information months in advance, doctors and expectant mothers can deploy simple, low-cost interventions to dramatically improve outcomes. It represents a fundamental rewiring of the mechanics of prenatal care, with profound implications for health, equity, and the economics of the healthcare industry.

The Science of Proactive Intervention

At the core of this new approach is the move away from generalized risk factors to individualized biology. The PreTRM® Test is not a genetic screen but a proteomic one, measuring the real-time ratio of two key proteins (IBP4 and SHBG) circulating in the mother’s blood. This ratio has been shown to be a powerful predictor of the body’s preparedness for labor.

The clinical validation for this predictive power comes from the PRIME trial, a rigorous 19-center randomized controlled study involving over 5,000 women. The results, published in Pregnancy, the peer-reviewed journal of the Society for Maternal-Fetal Medicine, are compelling. When physicians used the PreTRM® test to guide care, the rate of the earliest and most dangerous preterm births—those before 32 weeks—was reduced by more than 50%. Births before 35 weeks fell by over 30%.

Crucially, the test does not exist in a vacuum; it triggers a clear, low-cost action plan. The PRIME trial paired a high-risk result with a protocol of three established interventions: daily vaginal progesterone, low-dose aspirin, and more frequent telephonic check-ins with a nurse. This demonstrates that prediction is only valuable when coupled with effective prevention. “For years, all we could do was wait and react,” said Dr. Thaïs Aliabadi, a board-certified OB-GYN and vocal advocate for early screening. “Now we can predict a woman's risk early, and there is something we can actually do about it.”

The Economic Case for Early Screening

The clinical benefits translate directly into a powerful economic argument. The most significant financial driver in preterm birth is the cost of the Neonatal Intensive Care Unit (NICU), one of the most expensive forms of hospital care. The PRIME trial demonstrated that PreTRM-guided care led to a 20% reduction in NICU admissions. Extrapolating this, Sera Prognostics estimates that full national adoption of the test could prevent approximately 94,300 NICU admissions each year.

This potential for massive cost savings is the central pillar of the company’s market strategy. Sera has already secured a Medicare payment rate of $750 for the test’s CPT code. While this doesn't guarantee broad Medicare coverage for a test primarily used by a younger population, it serves as a critical pricing benchmark for negotiations with the commercial and state-level payers that matter most. It establishes a tangible value proposition for insurers: investing a few hundred dollars upfront on a test can avert tens of thousands of dollars in downstream NICU costs, not to mention the lifelong expenses associated with long-term complications of prematurity like cerebral palsy and learning disabilities.

The financial calculus is clear: shifting spending from high-cost, late-stage emergency care to low-cost, early-stage preventative screening offers a rare opportunity to both improve health outcomes and bend the healthcare cost curve.

A Potential Tool for Health Equity

Beyond the broad economic impact, this technology enters a healthcare landscape marked by deep-seated inequities. In the United States, Black women experience preterm birth at a rate nearly 50% higher than white women. A major contributor to this disparity is that traditional risk models fail a large portion of the population, particularly first-time mothers who account for 40% of all U.S. births and have no prior history to analyze.

The PreTRM® test, by relying on biological markers instead of patient history, offers a more objective and equitable screening method. It can flag a first-time mother in a high-risk group just as easily as a woman who has had previous preterm births. This potential to close the diagnostic gap is beginning to gain traction at the policy level. In a landmark move, Illinois Medicaid began covering proteomic prenatal testing, including the PreTRM® Test, on July 1, 2026. This decision makes Illinois a critical testing ground for how increased access in a diverse, publicly insured population can address long-standing health disparities.

“Most moms have no idea it’s something you can check for early, or that there’s anything you can do with that information,” noted Mary Alice Haney, co-host of the SHE MD podcast with Dr. Aliabadi. The goal, she explained, is to empower women to “ask their doctor, before anything goes wrong.” This empowerment is especially critical for women in historically underserved communities.

Navigating the Path to Standard of Care

Despite the promising data and clear economic argument, the road to becoming a new standard of care is complex. As a Laboratory Developed Test (LDT), the PreTRM® Test is regulated under CLIA and holds a coveted approval from New York State—a high bar for quality—but it does not have formal FDA approval. The primary hurdle, however, remains widespread payer adoption.

While the list price is $750, the company offers financial assistance and payment plans to mitigate out-of-pocket costs. Yet the ultimate success of the test hinges on convincing a fragmented ecosystem of private insurers and state Medicaid agencies that the upfront cost is a worthwhile investment. The Illinois decision provides a powerful precedent, but it is just one state. Sera Prognostics is now tasked with replicating that success across the country, a slow process of negotiation and evidence-building, payer by payer.

The push for adoption is thus a two-front effort: a top-down strategy of presenting compelling economic and clinical data to healthcare systems, and a bottom-up movement of informed patients and passionate clinicians demanding a more proactive approach to pregnancy. If successful, it will not only change the market for prenatal diagnostics but also fundamentally alter how we manage one of the most persistent and costly challenges in maternal and infant health.